Comparing the effectiveness of bivalent and monovalent COVID-19 vaccines against COVID-19 infection during the winter season of 2022-2023

• Verfasst von: Chae, Chungman [VerfasserIn]
• Verfasst von: Kim, Ryu Kyung [VerfasserIn]
• Verfasst von: Jang, Eun Jung [VerfasserIn]
• Verfasst von: Shim, Ji Ae [VerfasserIn]
• Verfasst von: Park, Eunkyung [VerfasserIn]
• Verfasst von: Lee, Kil Hun [VerfasserIn]
• Verfasst von: Hong, Sye Lim [VerfasserIn]
• Verfasst von: Aziz, Asma Binte [VerfasserIn]
• Verfasst von: Tadesse, Birkneh Tilahun [VerfasserIn]
• Verfasst von: Marks, Florian [VerfasserIn]
• Verfasst von: Tak, Sangwoo [VerfasserIn]
• Verfasst von: Lee, Sangwon [VerfasserIn]
• Verfasst von: Kwon, Donghyok [VerfasserIn]
• Titel: Comparing the effectiveness of bivalent and monovalent COVID-19 vaccines against COVID-19 infection during the winter season of 2022-2023
• Titelzusatz: a real-world retrospective observational matched cohort study in the Republic of Korea
• Verf.angabe: Chungman Chae, Ryu Kyung Kim, Eun Jung Jang, Ji Ae Shim, Eunkyung Park, Kil Hun Lee, Sye Lim Hong, Asma Binte Aziz, Birkneh Tilahun Tadesse, Florian Marks, Sangwoo Tak, Sangwon Lee, Donghyok Kwon
• E-Jahr: 2023
• Jahr: October 2023
• Umfang: 6 S.
• Illustrationen: Illustrationen
• Fussnoten: Online verfügbar: 11. August 2023, Artikelversion: 31. August 2023 ; Gesehen am 08.11.2023
• Titel Quelle: Enthalten in: International journal of infectious diseases
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1997
• Jahr Quelle: 2023
• Band/Heft Quelle: 135(2023) vom: Okt., Seite 95-100
• ISSN Quelle: 1878-3511
• DOI: doi:10.1016/j.ijid.2023.08.010
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Bivalent
• Sach-SW: COVID-19
• Sach-SW: Infection
• Sach-SW: Monovalent
• Sach-SW: Retrospective
• Sach-SW: Vaccination
• K10plus-PPN: 1869708342

Abstract

Objectives - To compare the effectiveness of bivalent and monovalent COVID-19 vaccines throughout the 2022-2023 winter season based on real-world data. - Methods - This retrospective observational matched cohort study used the national vaccination program and a surveillance dataset from the Republic of Korea, and included adults aged >18 years who received bivalent or monovalent COVID-19 vaccines between October 11, 2022, and December 17, 2022. Cox proportional hazard models were used to estimate the hazard ratio for COVID-19 infection between the groups. - Results - We included 29,245 matched individuals in the bivalent and monovalent vaccine groups, respectively. The bivalent vaccine recipients showed 12.2% (95% confidence interval [CI] 6.5-17.7%) additional protection against COVID-19 infection compared with the monovalent vaccine recipients. The additional protection provided by bivalent vaccines was significantly higher among residents of long-term care facilities (39.4%, 95% CI 21.6-53.1%). Maximum additional protection was observed 3 to 4 months after completing the vaccination (17.6%, 95% CI 6.6-27.3%). - Conclusion - Bivalent COVID-19 vaccines showed significantly better protection against infection than monovalent vaccines among adults during the 2022-2023 winter season. Our results highlight that immunization programs with bivalent vaccines comprising recent variants can be an effective measure to prepare for seasonal COVID-19 circulation.